We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Chocolate Consumption During Pregnancy Benefits Fetal Development

By HospiMedica International staff writers
Posted on 14 Feb 2016
A new study suggests that pregnant women who eat 30 grams of chocolate every day during pregnancy may benefit fetal growth and development.

Researchers at Université Laval (Canada) conducted a randomized controlled trial involving 129 expectant mothers with a singleton pregnancy between 11–14 weeks' gestation, and who had double-notching on uterine artery Doppler. More...
The women selected were randomized to either high-flavanol (HF) or low-flavanol (LF) chocolate, with 30 g consumed daily for 12 weeks. The main outcome measures were uterine artery Doppler pulsatility index (UtA PI), preeclampsia, gestational hypertension, placenta weight, and birthweight.

The results showed a significant decrease in uterine UtA PI among both chocolate groups, and that the difference between them was not significant, suggesting that both HF and LF chocolate may benefit fetal growth and development. At 12 weeks, no significant difference was noted between the HF and LF groups in the rate of preeclampsia and gestational hypertension. Placental weight and birthweight were also comparable between the two groups. The study was published in the January 2016 issue of the American Journal of Obstetrics & Gynecology.

“This study indicates that chocolate could have a positive impact on placenta and fetal growth and development, and that chocolate's effects are not solely and directly due to flavanol content,” concluded lead author Emmanuel Bujold, MD, and colleagues. “Previous epidemiological studies, along with our results, suggest that consumption of dark chocolate during pregnancy could help in the improvement of placental function and the reduction of preeclampsia.”

In women who are not pregnant, blood flow in the uterine artery is of a high pulsatility, with high systolic flow and low diastolic flow; a physiological early diastolic notch may be present. Resistance to blood flow normally drops gradually during gestation as greater trophoblastic invasion of the myometrium takes place; a persistent abnormally high resistance, however, often equates to a 70% chance of preeclampsia and 30% chance of intrauterine growth restriction (IUGR).

Related Links:

Université Laval



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The new 3D heart mapping system visualizes all four chambers in real time (Photo courtesy of UPV)

Whole-Heart Mapping Technology Provides Comprehensive Real-Time View of Arrhythmias

Cardiac arrhythmias can be difficult to diagnose and treat because current mapping systems analyze the heart one chamber at a time. This fragmented view forces clinicians to infer electrical activity they... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.